Keros Therapeutics Inc (KROS) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Keros Therapeutics Inc stock (KROS) is currently trading at $11.34. Keros Therapeutics Inc PE ratio is 4.89. Keros Therapeutics Inc PS ratio (Price-to-Sales) is 1.40. Analyst consensus price target for KROS is $22.57. WallStSmart rates KROS as Underperform.
- KROS PE ratio analysis and historical PE chart
- KROS PS ratio (Price-to-Sales) history and trend
- KROS intrinsic value — DCF, Graham Number, EPV models
- KROS stock price prediction 2025 2026 2027 2028 2029 2030
- KROS fair value vs current price
- KROS insider transactions and insider buying
- Is KROS undervalued or overvalued?
- Keros Therapeutics Inc financial analysis — revenue, earnings, cash flow
- KROS Piotroski F-Score and Altman Z-Score
- KROS analyst price target and Smart Rating
Keros Therapeutics Inc
📊 No data available
Try selecting a different time range
KROS Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Keros Therapeutics Inc (KROS)
KROS trades at a modest 9% premium above its Graham fair value of $15.64. Consider waiting for a pullback.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Keros Therapeutics Inc (KROS) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, price/book, profit margin. Concerns around operating margin and revenue growth. Fundamentals are solid but monitor weak areas for improvement.
Keros Therapeutics Inc (KROS) Key Strengths (5)
Trading below book value, meaning the market prices it less than net assets
Keeps $36 of every $100 in revenue as net profit
103.52% of shares held by major funds and institutions
Paying $1.40 for every $1 of annual revenue
Solid profitability: $20 profit per $100 equity
Supporting Valuation Data
Keros Therapeutics Inc (KROS) Areas to Watch (3)
Losing money on operations
Revenue declining -87.30%, a shrinking business
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
Keros Therapeutics Inc (KROS) Detailed Analysis Report
Overall Assessment
This company scores 51/100 in our Smart Analysis, earning a C- grade. Out of 8 metrics analyzed, 5 register as strengths (avg 9.0/10) while 3 fall into concern territory (avg 1.7/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book, Profit Margin, Institutional Own.. Valuation metrics including Price/Sales (1.40), Price/Book (0.71) suggest the stock is attractively priced. Profitability is solid with Return on Equity at 19.90%, Profit Margin at 35.60%.
The Bear Case
The primary concerns are Operating Margin, Revenue Growth, Market Cap. Growth concerns include Revenue Growth at -87.30%, which may limit upside. Profitability pressure is visible in Operating Margin at -7577.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Operating Margin improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 19.90% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at -87.30% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. The weight of evidence leans positive, with more strengths than concerns. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Price/Book, Profit Margin) and negatives (Operating Margin, Revenue Growth). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
KROS Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
KROS's Price-to-Sales ratio of 1.40x trades at a deep discount to its historical average of 615.41x (3th percentile). The current valuation is 100% below its historical high of 9456.6x set in May 2024, and 2% above its historical low of 1.38x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~92.6x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Keros Therapeutics Inc (KROS) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Keros Therapeutics Inc faces headwinds with declining revenue, though profitability provides a cushion. Revenue reached 244M with 87% decline year-over-year. Profit margins are strong at 35.6%, reflecting pricing power and operational efficiency.
Key Findings
Revenue contracted 87% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -27M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Keros Therapeutics Inc.
Bottom Line
Keros Therapeutics Inc faces challenges with declining revenue. While profitability provides a buffer, the long-term trajectory needs to improve. Watch for management's strategic response and whether the company can stabilize or pivot to new growth drivers.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(13 last 3 months)
| Insider | Type | Shares |
|---|---|---|
SEEHRA, JASBIR Director, CHIEF EXECUTIVE OFFICER | Sell | -7,015 |
| Insider | Type | Shares |
|---|---|---|
SEEHRA, JASBIR Director, CHIEF EXECUTIVE OFFICER | Buy | +62,500 |
Data sourced from SEC Form 4 filings
Last updated: 2:34:44 PM
About Keros Therapeutics Inc(KROS)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with a great unmet medical need. The company is headquartered in Lexington, Massachusetts.